Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Introduction: CAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells. Cytokine-induced killer (CIK) cells can be ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

The advent of epithelial cell lines, principally the tumour derived T84, Caco-2 and HT-29 cell lines, has offered opportunities to study influences of cytokines on epithelial function by taking a ...

Blocking and agonistic antibodies were used to define the role of Fas-mediated apoptosis in B cell regulation. Results Treg failed to restrain B cell activation, proinflammatory cytokine and antibody ...

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that forms in your white blood cells called lymphocytes. These cells are made by your lymphatic system, which plays an important role in immunity.

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...